Jaguar Health stock gets a special dividend with five-for-one conversion

Published on 10/04/2026 at 14:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jaguar Health stock closed at USD 3.66 on October 2, 2026, down 7.34 percent. Q2 revenue was USD 1.23 million against USD 4.24 million consensus.

JAGX, US47010C8543, Illustration mit AI erstellt.

Jaguar Health (ISIN US47010C8543) stock closed at USD 3.66 on Nasdaq on October 2, 2026, down 7.34 percent from the prior session. The company declared a special stock dividend on October 3, giving the market a defined timetable for a preferred-share distribution and later conversion.

Special dividend sets three dates

According to Newswire on October 3, 2026, the board declared Series R Convertible Preferred Stock for holders of voting common stock and certain warrants. Eligibility is based on ownership at the close of business on October 13, 2026, with payment scheduled for October 15, 2026.

Newswire reports that each preferred share will convert into five common shares on November 2, 2026. The release describes the distribution as protection against potential dilution while Jaguar evaluates strategic alternatives and advances its crofelemer program.

Revenue trails consensus in Q2

Jaguar's second-quarter revenue was USD 1.23 million, compared with USD 4.24 million expected by analysts, according to MarketBeat. The reported figure was USD 3.01 million below consensus, a gap of 71.0 percent based on the two published values.

MarketBeat lists a Sell consensus based on one research report. Its earnings page also shows second-quarter adjusted earnings per share of negative USD 15.70 against consensus of negative USD 782.25, although the revenue comparison remains the clearer operating checkpoint for the current update.

Stock remains far below yearly high

JAGX's October 2 closing price of USD 3.66 stood 99.71 percent below its 52-week high of USD 1,267.88 and USD 1.31 above its 52-week low of USD 2.35. The same session covered USD 3.50 to USD 4.30, with volume of 590,932 shares.

Jaguar Health describes its business as the development of plant-derived prescription drugs for complicated gastrointestinal diseases. Its Napo Pharmaceuticals and Napo Therapeutics units are developing oral crofelemer for rare intestinal-failure conditions, including microvillus inclusion disease and short bowel syndrome.

JAGX closed at USD 3.66

Jaguar Health stock closed at USD 3.66 on Nasdaq on October 2, 2026, at 4:00 p.m. ET. The special dividend timetable now puts October 13, October 15 and November 2 at the center of the stock's near-term corporate calendar.